Streetbeat News

ATNF

180 Life Sciences Corp.

https://180lifesciences.com

Industry

Biotechnology

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

180 Life Sciences Corp. (NASDAQ:ATNF) announced positive topline results from a clinical pharmacology study comparing two solid formulations of CBD with the FDA-approved drug Epidiolex. The study found that one of the solid forms was absorbed faster and exhibited higher maximal levels compared to Epidiolex.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:11 pm

180 Life Sciences Corp. (NASDAQ:ATNF) has been granted an extension by the Nasdaq Listing Qualifications Panel to regain compliance with Nasdaq's continued listing requirements. The company has until September 20, 2024, to meet the Equity Rule and maintain its listing on Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:06 pm

180 Life Sciences has been granted an extension by the Nasdaq Hearing Panel to regain compliance with continued listing requirements, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 12:20 pm

The article highlights significant intraday movements in health care stocks on Monday. Notable gainers include Mustang Bio (MBIO) with a 307.9% increase, Scinai Immunotherapeutics (SCNI) up by 62.17%, and Mirum Pharmaceuticals (MIRM) up by 20.79%. On the losing side, Aerovate Therapeutics (AVTE) saw a massive decline of 93.4%, Ovid Therapeutics (OVID) fell by 69.0%, and Bluejay Diagnostics (BJDX) dropped by 24.71%.

Portfolio Pulse from Benzinga Insights

June 17, 2024 | 4:31 pm

The article highlights the pre-market movements of 12 health care stocks on Friday. Notable gainers include Akanda (AKAN), Scorpius Holdings (SCPX), NovaBay Pharmaceuticals (NBY), ZimVie (ZIMV), Kintara Therapeutics (KTRA), and Doximity (DOCS). Significant losers include Reneo Pharmaceuticals (RPHM), Lucy Scientific Discovery (LSDI), SINTX Techs (SINT), 180 Life Sciences (ATNF), Dynatronics (DYNT), and Protalix BioTherapeutics (PLX).

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 12:07 pm

The article highlights significant intraday movements in health care stocks on Thursday. Notable gainers include Lucy Scientific Discovery (LSDI), SINTX Techs (SINT), Nanoviricides (NNVC), Scorpius Holdings (SCPX), Onconetix (ONCO), and NRX Pharmaceuticals (NRXP). Key losers are Eyenovia (EYEN), 180 Life Sciences (ATNF), Omeros (OMER), Elicio Therapeutics (ELTX), Biotricity (BTCY), and T2 Biosystems (TTOO). Several of these movements are linked to recent earnings reports.

Portfolio Pulse from Benzinga Insights

May 16, 2024 | 4:31 pm

180 Life Sciences announced the resignation of James N. Woody as CEO and board member, and Dr. Jonathan Rothbard as Chief Scientific Officer, both on May 7, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:09 pm

In Tuesday's pre-market session, health care stocks showed significant movement. Cyclacel Pharmaceuticals, GeneDx Hldgs, BioRestorative Therapies, Vaccinex, Addex Therapeutics, and Tenet Healthcare were among the gainers, with notable increases in their stock prices. On the other hand, SHL Telemedicine, Nektar Therapeutics, GlucoTrack, GE HealthCare Techs, Virios Therapeutics, and 180 Life Sciences experienced declines. The movements were influenced by factors such as Q1 earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 12:06 pm

In Tuesday's after-market session, several healthcare stocks showed notable movements. Gainers included 180 Life Sciences, ABVC BioPharma, Medpace Holdings, Adverum Biotechnologies, Black Diamond Therapeutic, and Verve Therapeutics, with increases ranging from 4.94% to 7.4%. On the losing side, Fresh2 Group, Kiora Pharmaceuticals, Alterity Therapeutics, Tiziana Life Sciences, Calidi Biotherapeutics, and Nuwellis saw declines between 7.06% and 12.9%. Medpace Holdings' stock rise followed their Q1 earnings release.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 8:31 pm

In Friday's after-market session, several healthcare stocks showed notable movements. Longeveron (LGVN) led the gainers with a 48.6% increase, while Elicio Therapeutics (ELTX) experienced the largest decline among the losers, dropping 10.3%. Other notable movers included Adial Pharmaceuticals (ADIL), Etao International Co (ETAO), and Inovio Pharmaceuticals (INO) with significant gains, and SINTX Techs (SINT), Cerus (CERS), and MediciNova (MNOV) among the losers.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.